
    
      Each of the following treatments will be evaluated on Day 1 of each period in a crossover
      fashion. The IV eravacycline (TP-434) and IV placebo will be double-blinded.

        -  Treatment A: Eravacycline (TP-434) 1.5 mg/kg administered intravenously over 60 minutes
           and one placebo oral tablet;

        -  Treatment B: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes
           and one moxifloxacin 400 mg oral tablet; and

        -  Treatment C: Placebo (0.9% sodium chloride) administered intravenously over 60 minutes
           and one placebo oral tablet.

      Subjects will be randomized to a treatment sequence according to a pre-generated treatment
      scheme. Subjects will receive a different treatment during each of the 3 periods.
    
  